Clinical significance of serum EGFR gene mutation and serum tumor markers in predicting tyrosine kinase inhibitor efficacy in lung adenocarcinoma

Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non–Small-cell Lung Cancer Patients

(2018) Ting-Hui Wu et al.   Clinical Lung Cancer

Use of SuperARMS EGFR Mutation Detection Kit to Detect EGFR in Plasma Cell-free DNA of Patients With Lung Adenocarcinoma

(2018) Shaohua Cui et al.   Clinical Lung Cancer

Association between advanced NSCLC T790 M EGFR-TKI secondary resistance and prognosis

(2018) Yuli Wang et al.   MEDICINE

Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer

(2018) Yanfeng Gao et al.   Scientific Reports

Review of economic analyses of treatment for non-small–cell lung cancer (NSCLC)

(2018) Alain Vergnenègre et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Clinical significance and diagnostic capacity of serum TK1, CEA, CA 19-9 and CA 72-4 levels in gastric and colorectal cancer patients

(2018) Shufang Ning et al.   Journal of Cancer

Influence of estrogen in non-small cell lung cancer and its clinical implications

(2018) Vianey Rodriguez-Lara et al.   Journal of Thoracic Disease

Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs)

(2017) Jia Zhong et al.   Journal of Thoracic Oncology

Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations

(2017) Pawel Krawczyk et al.   Oncology Letters

Progress and prospects of early detection in lung cancer

(2017) Sean Blandin Knight et al.   Open Biology

Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy

(2016) Yoshihisa Kobayashi et al.   CANCER SCIENCE

Impact of Race on Treatment and Survival among U.S. Veterans with Early-Stage Lung Cancer

(2016) Christina D. Williams et al.   Journal of Thoracic Oncology

Concomitance of P-gp/LRP Expression with EGFR Mutations in Exons 19 and 21 in Non-Small Cell Lung Cancers

(2016) Hong Wei et al.   YONSEI MEDICAL JOURNAL

High levels of EGFR expression in tumor stroma are associated with aggressive clinical features in epithelial ovarian cancer

(2016) Ke Wang et al.   OncoTargets and Therapy

Correlation between epidermal growth factor receptor tyrosine kinase inhibitor efficacy and circulating tumor cell levels in patients with advanced non-small cell lung cancer

(2016) Wenjie He et al.   OncoTargets and Therapy

Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer

(2016) Nicola Normanno et al.   Oncotarget

Survival Outcome Assessed According to Tumor Burden and Progression Patterns in Patients With Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma Undergoing Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

(2015) Yoon Ki Cha et al.   Clinical Lung Cancer

Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer

(2015) Gabriel Lima Lopes et al.   Jornal Brasileiro de Pneumologia

Detection of epidermal growth factor receptor (EGFR) exon 19 E746-A750 deletion and EGFR exon 21 point mutations in lung adenocarcinoma by immunohistochemistry: a comparative study to EGFR exons 19 and 21 mutations analysis using PCR followed by high-resolution melting and pyrosequencing

(2015) Devon Chabot-Richards et al.   JOURNAL OF HISTOTECHNOLOGY

Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer

(2015) Chen Mao et al.   MEDICINE

Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis

(2015) Sabrina Rossi et al.   Molecular Diagnosis & Therapy

Detection of epidermal growth factor receptor mutation in plasma as a biomarker in Chinese patients with early-stage non-small cell lung cancer

(2015) Kai Guo et al.   OncoTargets and Therapy

Differential diagnosis and cancer staging of a unique case with multiple nodules in the lung - lung adenocarcinoma, metastasis of colon adenocarcinoma, and colon adenocarcinoma metastasizing to lung adenocarcinoma

(2015) Yun Bai et al.   Thoracic Cancer

Association of Serum Levels of CEA, CA199, CA125, CYFRA21-1 and CA72-4 and Disease Characteristics in Colorectal Cancer

(2014) Wa Zhong et al.   PATHOLOGY & ONCOLOGY RESEARCH

Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC

(2014) Zhijie Wang et al.   PLoS One

Relationship between Epidermal Growth Factor Receptor Gene Mutations and Clinicopathological Features in Patients with Non-Small Cell Lung Cancer in Western Turkey

(2013) Olcun Umit Unal et al.   Asian Pacific Journal of Cancer Prevention

Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer

(2013) Kyoko Okamura et al.   LUNG CANCER

The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI

(2012) Zhen Huang et al.   Thoracic Cancer

Lung cancer in women: role of estrogens

(2010) Subhankar Chakraborty et al.   Expert Review of Respiratory Medicine

Epidermal growth factor receptor (EGFR) double-activating somatic mutations in exons 19 and 21 in Japanese non–small cell lung cancer patients

(2009) Katsuhiro Masago et al.   CANCER GENETICS AND CYTOGENETICS

Epidermal Growth Factor Receptor Gene Amplification Is Acquired in Association with Tumor Progression of EGFR-Mutated Lung Cancer

(2008) Y. Yatabe et al.   CANCER RESEARCH